Payment overview · 2025
General Payments
$451.00
23 reported records · 9 companies
Healthcare provider profile · identity verified
Xiaomei Chen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PLAINSBORO, NJ · NPI 1982767828
Verified facts
What the public records show
CMS Open Payments records show Xiaomei Chen, MD received $451.00 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Rexulti.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.91 | 34.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.45 | 16.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.18 | 14.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.43 | 10.5% | 3 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $35.68 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.74 | 6.8% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.61 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.04 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.96 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $451.00 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.19 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.84 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.18 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.18 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $61.47 | 4 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $35.68 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
132 | 78 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1102 | 278 |
| Amlodipine Besylate | Amlodipine Besylate | 700 | 176 |
| Losartan Potassium | Losartan Potassium | 424 | 113 |
| Metformin Hcl Er | Metformin Hcl | 333 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 67 |
| Lisinopril | Lisinopril | 197 | 50 |
| Alendronate Sodium | Alendronate Sodium | 185 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 34 |
| Metformin Hcl | Metformin Hcl | 169 | 49 |
| Valsartan | Valsartan | 168 | 44 |
| Vascepa | Icosapent Ethyl | 168 | 49 |
| Omeprazole | Omeprazole | 167 | 75 |
| Sertraline Hcl | Sertraline Hcl | 154 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 61 |
| Prolia | Denosumab | 132 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 42 |
| Mirtazapine | Mirtazapine | 124 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 62 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 118 | 54 |
| Famotidine | Famotidine | 111 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 106 | 67 |
| Azithromycin | Azithromycin | 96 | 64 |
| Donepezil Hcl | Donepezil Hcl | 95 | 25 |
| Carvedilol | Carvedilol | 94 | 26 |
| Memantine Hcl | Memantine Hcl | 92 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 82 | 16 |
| Finasteride | Finasteride | 79 | 20 |
| Tradjenta | Linagliptin | 79 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 19 |
| Simvastatin | Simvastatin | 75 | 19 |
| Trazodone Hcl | Trazodone Hcl | 75 | 25 |
| Azelastine Hcl | Azelastine Hcl | 74 | 30 |
| Januvia | Sitagliptin Phosphate | 72 | 16 |
| Memantine Hcl Er | Memantine Hcl | 72 | 13 |
| Furosemide | Furosemide | 71 | 21 |
| Meloxicam | Meloxicam | 71 | 45 |
| Icosapent Ethyl | Icosapent Ethyl | 70 | 39 |
| Montelukast Sodium | Montelukast Sodium | 66 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 29 |
| Acarbose | Acarbose | 62 | 20 |
| Gabapentin | Gabapentin | 61 | 27 |
| Eliquis | Apixaban | 60 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 24 |
| Allopurinol | Allopurinol | 57 | 17 |
| Potassium Chloride | Potassium Chloride | 54 | 13 |
| Farxiga | Dapagliflozin Propanediol | 53 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Cyclosporine | Cyclosporine | 52 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 33 |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 13 |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 30 |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Linzess | Linaclotide | 38 | 12 |
| Prednisone | Prednisone | 38 | 18 |
| Zenpep | Lipase/Protease/Amylase | 38 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 11 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Hydrocortisone | Hydrocortisone | 26 | 19 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 18 |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | 11 |
| Lagevrio (Eua) | Molnupiravir | 23 | 19 |
| Ozempic | Semaglutide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 22 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | 13 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 15 |
| Cefazolin Sodium | Cefazolin Sodium | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $451.00 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, JARDIANCE, OTEZLA, PYRUKYND, REPATHA, REXULTI, The Cologuard Plus Collection Kit, Wegovy, Zunveyl | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error